lifestyle.californiaconsumerbanking.com

Author: Edgewise Therapeutics

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

May 12, 2026
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

May 9, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

May 8, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

May 4, 2026
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

May 1, 2026
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

April 30, 2026
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

April 29, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

April 29, 2026
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

April 29, 2026
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

March 9, 2026